Basic Nimotop Information

• INN (International Nonproprietary Name): Nimodipine
• Brand Names Available In Canada (English): Nimotop; Nymalize; Nimodipina; other generics (brands and registration vary by region)
• ATC Code: C08CA06
• Forms & Dosages: Soft gelatin capsule 30 mg; oral liquid 30 mg/10 mL, 60 mg/10 mL, 60 mg/20 mL; bottles with dosing syringe or 30 mg capsules in blister strips/tubs
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription only (Rx)

Everyday Use And Best Practices

Morning Vs Evening Dosing In Canadian Routines

Patients ask how to fit a 4‑hour nimotop schedule into real life while recovering from aneurysmal SAH.

Nimodipine is given 60 mg every four hours for 21 days and that schedule will cross day and night.

Hospital nursing teams usually manage the four‑hour regimen while the patient is inpatient.

When the patient goes home or to rehab, family caregivers or a home‑care nurse should be assigned dosing duties.

Set alarms, use smartphone reminders, or ask the pharmacy for blister packing to reduce missed doses.

Rural patients should arrange pharmacy delivery from chains like Shoppers Drug Mart or London Drugs to keep doses on time.

Plan for brief waking at night rather than skipping doses, because consistent timing matters for the post‑SAH protocol.

• Sample 24‑hour grid: 06:00, 10:00, 14:00, 18:00, 22:00, 02:00.
• NG tube notes: use oral solution via syringe for accurate NG dosing and label the syringe per dose time.

Taking With Or Without Meals

Nimodipine may be taken with or without food, but heavy meals can change gastric emptying and nausea risk.

Advise patients to be consistent with timing relative to meals to reduce stomach upset, especially with high‑fat northern staples or varied multicultural meals common across Canada.

For the oral solution, use the supplied syringe for accurate measurement.

Avoid alcohol‑containing formulations in patients with alcohol sensitivity or a history of alcoholism; check excipients on the bottle.

Safety Priorities

Who Should Avoid It (Health Canada Advisories)

Check absolute contraindications before dispensing nimotop.

Do not use nimodipine in patients with known hypersensitivity to the drug or any formulation component.

Avoid in severe hypotension or shock because further blood‑pressure lowering is dangerous.

Intravenous administration is strictly contraindicated due to reports of severe, potentially fatal cardiovascular events.

Patients taking strong CYP3A4 inhibitors such as some azole antifungals or macrolide antibiotics face increased nimodipine levels and risk profound hypotension; pharmacist review is required.

Pregnant or breastfeeding patients should use nimodipine only if the clinical benefit justifies the risk and after discussion with perinatal care teams.

• Contraindications: hypersensitivity; severe hypotension/shock; do not administer IV.
• Medications to flag: strong CYP3A4 inhibitors (antifungals, certain macrolides).
• Pregnancy/breastfeeding: use only if benefits outweigh risks; consult specialist.

Activities To Limit (Driving, Workplace Safety)

Nimodipine can cause light‑headedness, hypotension and bradycardia in some patients.

Advise patients not to drive or operate heavy machinery until they know how nimotop affects them.

For those returning to manual labour, logging, mining, or driving professions, document workplace restrictions in return‑to‑work plans supported by the employer.

Contact a clinician urgently if syncope, severe dizziness, or fainting occurs.

• Workplace modifications: temporary reassignment away from safety‑sensitive tasks.
• When to call clinician: repeated fainting, symptomatic hypotension, new chest pain or severe bradycardia.

Dosage And Adjustments

General Regimen (DIN References)

The standard adult oral regimen is 60 mg every four hours for 21 consecutive days, started within 96 hours of the SAH.

Capsules are commonly 30 mg soft gelatin forms; two capsules equal one 60 mg dose.

Oral solutions come in 30 mg/10 mL and 60 mg/10 mL (and other concentrations) and are helpful when swallowing is impaired.

Check the pack for the Drug Identification Number (DIN) and the local product monograph when dispensing.

Use the oral solution for NG tube administration because it simplifies accurate dosing and reduces risk of capsule blocking.

Special Cases (Elderly, Comorbidities)

Elderly patients may be more sensitive to hypotension and should have more frequent blood‑pressure monitoring.

Review and consider adjusting other antihypertensives to reduce falls risk while on nimotop.

Hepatic impairment increases nimodipine bioavailability and may require dosing reduction or closer BP checks.

No specific renal dosing adjustments are documented, but clinical monitoring is advised.

Children: safety and efficacy are not established and nimodipine is not routinely recommended in paediatric patients.

• Monitoring schedule: baseline BP/HR, then daily while inpatient and regular checks after discharge.
• Medication review: check for CYP3A4 inhibitors and overlapping antihypertensives.
• Fall prevention: gait assessment and home safety review for elderly patients.

User Testimonials

Positive Reports From Canadian Patients

Patients often say relief comes from knowing nimodipine is standard care after aneurysmal SAH.

Many praise attentive hospital dosing and smooth handover when oral solution is provided for NG administration.

Urban patients in Toronto, Vancouver and Montreal report easy pharmacy access and discharge planners arranging coverage.

Rural patients frequently mention mail‑order pharmacy deliveries and community nursing follow‑up as crucial to adherence.

• "Hospital nurses never missed a dose; pharmacy arranged blister packs for home." — theme: adherence support.
• "The oral solution made NG dosing straightforward." — theme: practical access.
• "Delivery to my rural town kept the schedule on track." — theme: access in remote areas.

Common Challenges In Forums

On Canadian forums such as Reddit and regional health boards, recurring concerns include night‑time dosing interruptions and out‑of‑pocket costs when provincial plans don’t cover outpatient supply.

Users also report dizziness or low blood pressure leading to temporary withholding and emphasise calling the prescriber rather than stopping abruptly.

Misinformation like intravenous use of nimodipine appears occasionally and should be corrected using the product monograph.

Buying Guide

Pharmacy Sources (Shoppers, Rexall, Jean Coutu, London Drugs)

Nimotop is prescription only and usually initiated in hospital for SAH treatment.

Community pharmacies including Shoppers Drug Mart, Rexall, Jean Coutu in Quebec and London Drugs in Western Canada can order branded or generic 30 mg capsules or the oral solution.

Rural clinics may require a 24–48 hour ordering lead time, so arrange delivery or community nursing support before discharge.

Ask your pharmacist to confirm the DIN, check formulation excipients (alcohol in some oral solutions) and advise on storage and stability.

• What to ask your pharmacist: DIN, brand vs generic, alcohol content in solution, expected delivery time, and storage instructions.

Price Comparison (In‑Store Vs Online, Cross‑Border Notes)

Prices vary by brand, generic status and provincial coverage; hospital inpatient supply is standard but outpatient reimbursement varies by provincial plans.

Patients should check Ontario Drug Benefit, BC PharmaCare or RAMQ and private insurance for coverage and any prior‑authorization requirements.

Cross‑border options such as Nymalize oral solution exist in the US, but importing medication can be subject to special access rules and importation limits—consult Health Canada and your provincial plan before considering cross‑border purchase.

In our online pharmacy, nimotop is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

What’s Inside And How It Works

Ingredients Overview

The active ingredient is nimodipine (INN).

Common formulations include 30 mg soft gelatin capsules and oral liquids such as 30 mg/10 mL and 60 mg/10 mL, supplied with dosing syringes.

Excipients vary by manufacturer; some oral solutions contain alcohol so screen patients for alcohol sensitivity or history of alcoholism.

Check the product monograph for full excipient listings and hypersensitivity warnings before dispensing.

• Formulation quick facts: 30 mg capsule (soft gelatin); oral solution 30 mg/10 mL, 60 mg/10 mL; dosing syringe included with liquid bottles.
• Excipients to flag: alcohol in some solutions; manufacturer‑specific additives—consult the SmPC.

Mechanism Basics

Nimodipine is an L‑type dihydropyridine calcium channel blocker with relative cerebral vascular selectivity (ATC C08CA06).

Its role after aneurysmal SAH is to reduce the risk of delayed cerebral ischemia by limiting cerebral vasospasm and improving microcirculatory perfusion.

Unlike systemic antihypertensives, its therapeutic effect is specific to neurological injury contexts and supported by the standard post‑SAH regimen.

Main Indications

Approved Uses In Canada

The primary evidence‑based indication is prevention and treatment of neurological deficits after aneurysmal subarachnoid haemorrhage (SAH).

Therapy is hospital‑initiated within 96 hours of the SAH event and typically continued as 60 mg every four hours for 21 days.

Prescribers and dispensers should confirm Health Canada status and the DIN on the pack where available.

Off‑Label Uses By Canadian Physicians

Off‑label nimodipine use is clinician‑dependent and may be considered in rare cerebral vasospasm scenarios, but routine use outside post‑SAH care is not established.

Any off‑label decision should be discussed with neurosurgery or neurology teams and documented on provincial health records with informed consent.

• Questions to ask if offered off‑label: what evidence supports this use, what alternative treatments exist, and what monitoring will occur?

Interaction Warnings

Food Interactions (Alcohol, Caffeine)

Some oral solutions contain alcohol, so advise patients and caregivers to check excipients if alcohol avoidance is necessary.

Alcohol can potentiate hypotension, so counsel patients to avoid co‑consumption where possible while on nimotop.

Caffeine has no major contraindication with nimodipine, but advise consistent intake to reduce blood‑pressure variability if relevant.

• Tell the pharmacist if alcohol must be avoided for medical, cultural or religious reasons so an alternative formulation can be considered.

Drug Conflicts (Health Canada Database)

Major interactions involve strong CYP3A4 inhibitors such as certain azole antifungals and some macrolide antibiotics that can raise nimodipine levels and cause severe hypotension.

Combining nimodipine with other blood‑pressure lowering drugs increases the risk of syncope and falls; perform a full medication reconciliation at discharge.

Pharmacists should use provincial interaction tools alongside Health Canada resources to identify and manage conflicts.

Latest Evidence And Insights

Randomized trials and clinical guidelines support nimodipine as standard of care to reduce delayed ischemic deficits after aneurysmal SAH.

The established regimen of 60 mg every four hours for 21 days has historical and guideline backing and early initiation within 96 hours is emphasised in the literature.

For Canadian applicability, consult neurosurgical society guidelines and provincial stroke networks such as the Ontario Stroke Network for local protocols and updates.

• Where to find updates: Health Canada Drug Product Database, provincial stroke units, peer‑reviewed journals and neurosurgical society guidance.

Alternative Choices

No direct pharmaceutical equivalent is licensed for the specific post‑SAH role that nimodipine fills.

Other L‑type dihydropyridine calcium channel blockers such as amlodipine or nifedipine are used for systemic hypertension but are not approved for preventing delayed ischemic deficits after SAH.

Decisions about alternatives should be made by neurology or neurosurgery teams, and in many cases timely transfer to a tertiary centre is preferable to medical substitution.

• Pros/cons checklist: systemic BP effects vs cerebral selectivity; evidence base; monitoring requirements.

Regulation Snapshot

Nimodipine is prescription‑only in the jurisdictions surveyed in the product data.

Always verify the product’s Health Canada status and the DIN on the pack or via the Drug Product Database before prescribing or dispensing.

Provincial drug benefit plans may have differing coverage criteria; hospital‑initiated SAH treatment is usually supported but outpatient reimbursement varies.

• Regulatory checks: confirm Health Canada DPIN/DIN, consult the SmPC for formulation‑specific details.
• Pharmacy practice notes: confirm brand vs generic interchangeability and screen for alcohol in oral solutions.
• Document in the chart: indication, start time relative to SAH, monitoring plan and counselling provided.

Cross‑border considerations: US oral solutions (for example Nymalize) exist, but importing medication may require special access rules—advise patients to consult Health Canada and provincial plans before attempting cross‑border purchases.

FAQ Section

Q1: Can I Stop Nimodipine If I Feel Dizzy?

No—contact your prescriber or pharmacist for advice rather than stopping abruptly.

Dizziness or hypotension may require dose review, adjustment of other antihypertensives, or closer monitoring.

Q2: Is Nimodipine Available At My Local Pharmacy?

Ask your pharmacy to order branded Nimotop or a generic nimodipine product and confirm the DIN and expected availability.

Large chains and hospital pharmacies typically stock or can source it within 24–48 hours, but confirm lead times for rural locations.

Q3: Will Provincial Drug Plans Cover The Cost?

Coverage varies by province and by inpatient versus outpatient status.

Hospital inpatient therapy for SAH is typically supplied, while outpatient coverage depends on the provincial formulary and private insurance.

Q4: Can I Take Nimodipine With My Antifungal Antibiotic?

Not without clinician review because strong CYP3A4 inhibitors such as some azole antifungals can raise nimodipine levels and cause severe hypotension.

• Quick actions: call your prescriber or pharmacist; have a current medication list, latest BP readings, and the DIN or product name available when you call.

Guidelines For Proper Use

Follow hospital and provincial stroke unit protocols: start nimodipine within 96 hours of SAH and continue 60 mg every four hours for 21 days.

Prefer the oral route; use capsules or oral solution via NG tube if required, and never administer intravenously.

Store nimodipine below 25°C and protect it from light; keep all medicines out of reach of children.

• Immediate actions at discharge: provide a complete medication list, confirm pharmacy contact for refills or delivery, and start a BP/HR log for home monitoring.
• Pharmacist role: verify DIN and formulation, review for CYP3A4 interactions, counsel on side effects including hypotension and nausea, and supply bilingual information where required.
• When to seek urgent care: syncope, severe hypotension, chest pain or new severe neurological deficit.

Delivery Across Canada (English)